OMEPRAZOLE

PeakSM

omeprazole

NDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Proton Pump Inhibitors

Pharmacologic Class:

Proton Pump Inhibitor

Clinical Trials (5)

NCT07149415Phase 1Completed

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

Started Sep 2025
22 enrolled
Healthy Volunteer
NCT06991179Phase 1Completed

A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants

Started May 2025
36 enrolled
Healthy
NCT07007806Phase 1Completed

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Started May 2025
20 enrolled
Healthy Volunteer Study
NCT06948006Phase 1Completed

A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants

Started Apr 2025
32 enrolled
Healthy Participants
NCT06494761Phase 1Completed

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Started Jul 2024
16 enrolled
Healthy

Loss of Exclusivity

LOE Date
Dec 8, 2036
131 months away
Patent Expiry
Dec 8, 2036

Patent Records (2)

Patent #ExpiryTypeUse Code
10076494
Dec 8, 2036
Product
10835488
Dec 8, 2036
Product